Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Non-cash Items (2020 - 2025)

Historic Non-cash Items for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $59.8 million.

  • Tango Therapeutics' Non-cash Items rose 8249.31% to $59.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.8 million, marking a year-over-year increase of 8249.31%. This contributed to the annual value of $11.2 million for FY2024, which is 4206.03% up from last year.
  • Tango Therapeutics' Non-cash Items amounted to $59.8 million in Q3 2025, which was up 8249.31% from $14.3 million recorded in Q2 2025.
  • Over the past 5 years, Tango Therapeutics' Non-cash Items peaked at $69.7 billion during Q3 2021, and registered a low of $4.1 million during Q3 2022.
  • Moreover, its 5-year median value for Non-cash Items was $61.2 million (2023), whereas its average is $12.0 billion.
  • In the last 5 years, Tango Therapeutics' Non-cash Items skyrocketed by 67483.85% in 2021 and then tumbled by 9999.42% in 2022.
  • Quarter analysis of 5 years shows Tango Therapeutics' Non-cash Items stood at $51.4 billion in 2021, then plummeted by 52.8% to $24.3 billion in 2022, then tumbled by 99.74% to $62.6 million in 2023, then crashed by 82.13% to $11.2 million in 2024, then surged by 434.43% to $59.8 million in 2025.
  • Its last three reported values are $59.8 million in Q3 2025, $14.3 million for Q2 2025, and $11.2 million during Q4 2024.